STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 90 filers reported holding STOKE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,017,718 | -71.9% | 258,422 | -24.0% | 0.00% | -100.0% |
| Q2 2023 | $3,615,364 | +47.8% | 340,145 | +15.8% | 0.00% | 0.0% |
| Q1 2023 | $2,445,748 | +90651.3% | 293,632 | +0.6% | 0.00% | 0.0% |
| Q4 2022 | $2,695 | -99.9% | 292,007 | -13.9% | 0.00% | -50.0% |
| Q3 2022 | $4,353,000 | +24.3% | 338,996 | +27.9% | 0.00% | +100.0% |
| Q2 2022 | $3,501,000 | +9.6% | 265,021 | +74.7% | 0.00% | 0.0% |
| Q1 2022 | $3,194,000 | +84.5% | 151,660 | +110.2% | 0.00% | 0.0% |
| Q4 2021 | $1,731,000 | +52.1% | 72,142 | +61.3% | 0.00% | – |
| Q3 2021 | $1,138,000 | -67.9% | 44,719 | -57.6% | 0.00% | -100.0% |
| Q2 2021 | $3,547,000 | -15.9% | 105,383 | -3.2% | 0.00% | 0.0% |
| Q1 2021 | $4,218,000 | +71.1% | 108,823 | +173.3% | 0.00% | 0.0% |
| Q4 2020 | $2,465,000 | +898.0% | 39,813 | +439.4% | 0.00% | – |
| Q3 2020 | $247,000 | – | 7,381 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |